Eli Lilly and Company(LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest News & Analysis
Eli Lilly (LLY): Regulatory Challenges and Growth Opportunities
Eli Lilly (LLY) navigates regulatory changes, market competition, and healthcare policies. Key is Lepodisiran, a therapy that reduces heart disease risk, positioning it for growth.
Eli Lilly (LLY): Zepbound Lawsuits, Tariffs, and Growth
Eli Lilly (LLY) navigates Zepbound lawsuits, tariff risks, and promising drug developments. A detailed analysis for investors.
Eli Lilly (LLY): Alzheimer's Setback, Weight-Loss Hope
Eli Lilly (LLY) navigates EU rejection of Kisunla, promising weight-loss drug Orforglipron, LillyDirect expansion, and VIG ETF inclusion amid macroeconomic challenges.
Eli Lilly (LLY): Strategic Moves, Obesity Drug Race, and Future Outlook
Eli Lilly navigates the obesity drug race with strategic acquisitions and awaits Orforglipron trial results, shaping its competitive future against Novo Nordisk.
Eli Lilly (LLY): Obesity Drugs, AI Innovation, and Growth Analysis
Eli Lilly's strategic moves in obesity drugs, AI, and global expansion drive growth. Financial analysis reveals strong revenue and net income growth, but high valuation warrants caution.
Eli Lilly: Mounjaro's India Launch, Financial Growth, and R&D
Eli Lilly's Mounjaro launches in India, financial growth surges, and R&D investments drive innovation. Investor confidence remains strong amid competitive dynamics.
Eli Lilly (LLY): Market Volatility and Competitive Pressures
Eli Lilly (LLY) navigates market volatility with competitive pressures from AbbVie in obesity and potential drug pricing regulations, balanced by breakthroughs in dermatology.
Eli Lilly (LLY): GLP-1 Dominance and Dermatology Innovations
Eli Lilly (LLY) is experiencing growth and innovation across its pharmaceutical portfolio. Dermatology breakthroughs, GLP-1 dominance, and LillyDirect highlight its strategic direction.
Eli Lilly (LLY) News: Manufacturing, Pricing, and Growth Analysis
Eli Lilly is expanding manufacturing, innovating Zepbound pricing, and competing in the GLP-1 market. Jaypirca's EU approval and ad campaigns against unapproved drugs highlight strategic moves.
Eli Lilly's $27B US Manufacturing Push & Jaypirca's EU Approval
Eli Lilly expands US manufacturing with a $27B investment amid rising demand for Zepbound & Mounjaro. Plus, Jaypirca receives positive EU recommendation.
Eli Lilly's $27B US Investment: Tariffs, Zepbound, and Pharma Reshoring
Eli Lilly's $27B US investment signals a strategic shift amid rising demand for Zepbound and Mounjaro, addressing tariffs and bolstering supply chain resilience.
Eli Lilly's Zepbound Strategy: Pricing, Competition, Growth
Eli Lilly strategically adjusts Zepbound pricing, navigates competition with Novo Nordisk, and expands access via LillyDirect. The company's R&D pipeline extends beyond weight loss.
Eli Lilly's Zepbound Strategy: Navigating Competition and Policy Risks
Eli Lilly strategically navigates the GLP-1 market with Zepbound price adjustments and LillyDirect, facing competition from Novo Nordisk and policy risks.
Eli Lilly's 2025 Growth Strategy: Pipeline, Weight Loss & AI Impact
Eli Lilly navigates 2025 with GLP-1 therapies, strategic R&D investments, and expansion into new therapeutic areas, demonstrating innovation and long-term value creation.
Eli Lilly's Bold Moves: Weight Loss, Alzheimer's, and the Future
Eli Lilly strategically shifts to Alzheimer's and ALS, leveraging GLP-1 success. A $550M weight-loss pill investment and projected 32% revenue growth highlight potential.
Eli Lilly's Strategic Shift: Weight Loss Windfall Fuels Alzheimer's and ALS Push
Eli Lilly leverages its weight loss drug success to invest in groundbreaking Alzheimer's and ALS research, driving a strategic pivot.
Eli Lilly's GLP-1 Drugs: A Market-Shaping Force in 2025
This comprehensive analysis examines Eli Lilly's GLP-1 drugs market impact, strategic developments, and future growth opportunities.
Eli Lilly's GLP-1 Drugs Fuel Growth Amid Competitive Pressure
Latest analysis reveals Eli Lilly’s strategic GLP-1 focus and diversified R&D, driving robust revenue growth and future potential.